CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-24 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +4,990 | $2.14 | $11K | 6,281 |
| 2023-11-24 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −4,920 | $15.74 | $77K | 1,361 |
| 2023-11-24 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −70 | $16.07 | $1K | 1,291 |
| 2023-11-24 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −371 | 18,331 | ||
| 2023-11-24 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,619 | 139,285 | ||
| 2023-11-22 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +2,412 | $1.74 | $4K | 3,703 |
| 2023-11-22 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +6,970 | $2.14 | $15K | 10,673 |
| 2023-11-22 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −9,382 | $15.17 | $142K | 1,291 |
| 2023-11-22 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −905 | 2,717 | ||
| 2023-11-22 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,507 | 15,068 | ||
| 2023-11-22 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −648 | 18,702 | ||
| 2023-11-22 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,322 | 143,904 | ||
| 2023-11-22 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +4,200 | $1.74 | $7K | 5,809 |
| 2023-11-22 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +9,600 | $2.14 | $21K | 15,409 |
| 2023-11-22 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −13,800 | $15.00 | $207K | 1,609 |
| 2023-11-22 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,700 | 16,008 | ||
| 2023-11-22 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,500 | 10,588 | ||
| 2023-11-22 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,500 | 12,394 | ||
| 2023-11-22 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,600 | 38,508 | ||
| 2023-11-22 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,500 | 46,232 |
Page 12 of 16 · 315 trades